GlassScriptPhysician profile
Matthew P Sniezek
NPI 1053675405
$26,285.95
in general payments reported to CMS, 2019-2025
59 companies · $3,711 in 2025
The $3,711 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,586 · 2020: $3,275 · 2021: $4,000 · 2022: $3,694 · 2023: $3,561 · 2024: $3,459 · 2025: $3,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,621.93 |
| Education | $108.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,320.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $2,947.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,362.77 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $1,876.02 | 2019-2025 | |
| Lilly USA, LLC | $1,594.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,548.27 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $1,419.50 | 2019-2025 | Xarelto, Spravato |
| Abbvie INC. | $1,370.69 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk As | $1,248.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,141.03 | 2019-2025 | Farxiga, Breztri, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $832.21 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $643.88 | 2019-2022 | |
| Astellas Pharma US INC | $633.41 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $601.71 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Novartis Pharmaceuticals Corporation | $576.86 | 2019-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sniezek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.